Investor Hub

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases.

Latest investor presentation
Latest clinical presentation
Latest quarterly earnings
Annual report
Global ticker
NASDAQNVAX
NASDAQNVAX
FormDescriptionDateFormat
UPLOADCorrespondence from the SEC to the FilerNov 16, 2005Open Correspondence from the SEC to the Filer in HTML.Open Correspondence from the SEC to the Filer in DOC file.Open Correspondence from the SEC to the Filer in PDF file.Open Correspondence from the SEC to the Filer in XLS file.
CORRESPCorrespondence from the Filer to the SECNov 15, 2005Open Correspondence from the Filer to the SEC in HTML.Open Correspondence from the Filer to the SEC in DOC file.Open Correspondence from the Filer to the SEC in PDF file.Open Correspondence from the Filer to the SEC in XLS file.
SC 13D/AAmendment to a SC 13D filingNov 4, 2005Open Amendment to a SC 13D filing in HTML.Open Amendment to a SC 13D filing in DOC file.Open Amendment to a SC 13D filing in PDF file.Open Amendment to a SC 13D filing in XLS file.
CORRESPCorrespondence from the Filer to the SECOct 31, 2005Open Correspondence from the Filer to the SEC in HTML.Open Correspondence from the Filer to the SEC in DOC file.Open Correspondence from the Filer to the SEC in PDF file.Open Correspondence from the Filer to the SEC in XLS file.
SC 13D/AAmendment to a SC 13D filingOct 13, 2005Open Amendment to a SC 13D filing in HTML.Open Amendment to a SC 13D filing in DOC file.Open Amendment to a SC 13D filing in PDF file.Open Amendment to a SC 13D filing in XLS file.
SC 13D/AAmendment to a SC 13D filingSep 6, 2005Open Amendment to a SC 13D filing in HTML.Open Amendment to a SC 13D filing in DOC file.Open Amendment to a SC 13D filing in PDF file.Open Amendment to a SC 13D filing in XLS file.
CORRESPCorrespondence from the Filer to the SECJul 26, 2005Open Correspondence from the Filer to the SEC in HTML.Open Correspondence from the Filer to the SEC in DOC file.Open Correspondence from the Filer to the SEC in PDF file.Open Correspondence from the Filer to the SEC in XLS file.
UPLOADCorrespondence from the SEC to the FilerJul 12, 2005Open Correspondence from the SEC to the Filer in HTML.Open Correspondence from the SEC to the Filer in DOC file.Open Correspondence from the SEC to the Filer in PDF file.Open Correspondence from the SEC to the Filer in XLS file.
Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.

I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine

Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription 

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at ir@novavax.com

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.